Loading…
Employees: 4,697
Size Nanjing Pharmaceutical (600713.SS) is a China Health Care company (Medical Distributors) with a market value of $1.03B, the 2252nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.32 on 6 Nov 2026.
Performance Over six months the shares gained 0.8%, against -6.8% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median +4.1%); the operating margin is 2.5% (peer median 1.3%).
Valuation It trades at 0.3× enterprise value to sales against a peer median of 0.6× (7th cheapest of 21).
Capital Return on invested capital runs 0.8 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥55.5B | CN¥54.9B | CN¥53.6B | CN¥53.5B | CN¥50.2B |
| Revenue growth | — | +2% | 0% | +7% | — |
| Gross profit | CN¥3.51B | CN¥3.06B | CN¥3.04B | CN¥2.98B | CN¥2.93B |
| EBITDA | n/a | CN¥1.60B | CN¥1.78B | CN¥1.77B | CN¥1.64B |
| Net income | CN¥638M | CN¥625M | CN¥571M | CN¥578M | CN¥596M |
| Free cash flow | -CN¥1.70B | -CN¥153M | CN¥1.59B | CN¥1.75B | -CN¥835M |
| Capital expenditure | CN¥215M | CN¥251M | CN¥545M | CN¥158M | CN¥155M |
| Total debt | CN¥12.1B | CN¥9.04B | CN¥12.6B | CN¥11.6B | CN¥15.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600713.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.2% | +0.8% | 5th highest of 21 |
| 6-month return | +0.8% | -6.8% | 9th highest of 21 |
| Distance from 52-week high | -20.0% | -19.8% | 11th highest of 21 |
| Revenue growth (TTM) | +3.0% | +4.1% | 10th lowest of 21 |
| Operating margin | 2.5% | 1.3% | 9th highest of 21 |
| EV / Sales | 0.3× | 0.6× | 7th cheapest of 21 |
| ROIC minus cost of capital | +0.8 pp | +0.4 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | 0.3× | n/a | n/a |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 1.3× | -1.0% | +6.3% |
| Shanghai Haohai Biological Technology 688366.SS | China | $946M | -24% | -9% | -2% | 2.0× | 18.9% | +13.2% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 0.7× | -5.9% | +1.2% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | 0.6× | -1.3% | +17.9% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 0.2× | -14.7% | +7.6% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 0.1× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | 0.5× | n/a | n/a |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | 2.4× | 0.3% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | 0.8× | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 0.1× | -7.1% | +3.8% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | 1.2× | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | 4.1× | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | 0.6× | 59.0% | -7.8% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 0.1× | -11.9% | +3.2% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | 0.1× | 0.4% | +2.6% |